

Carolina Sales Vieira

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8585819/publications.pdf>

Version: 2024-02-01

78
papers

1,560
citations

279798
23
h-index

361022
35
g-index

84
all docs

84
docs citations

84
times ranked

1985
citing authors

#	ARTICLE	IF	CITATIONS
1	High prevalence of polycystic ovary syndrome in women born small for gestational age. Human Reproduction, 2010, 25, 2124-2131.	0.9	90
2	Unfavorable lipid profile in women with endometriosis. Fertility and Sterility, 2010, 93, 2433-2436.	1.0	84
3	Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception, 2009, 80, 519-526.	1.5	81
4	Increased arterial stiffness in nonobese women with polycystic ovary syndrome (PCOS) without comorbidities: one more characteristic inherent to the syndrome?. Clinical Endocrinology, 2009, 71, 406-411.	2.4	69
5	Pathogenesis of polycystic ovary syndrome: multifactorial assessment from the foetal stage to menopause. Reproduction, 2015, 150, R11-R24.	2.6	69
6	Effect of Antiretroviral Therapy Including Lopinavir/Ritonavir or Efavirenz on Etonogestrel-Releasing Implant Pharmacokinetics in HIV-Positive Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 378-385.	2.1	59
7	Presentation and treatment of uterine leiomyoma in adolescence: a systematic review. BMC Women's Health, 2015, 15, 4.	2.0	49
8	Both a combined oral contraceptive and depot medroxyprogesterone acetate impair endothelial function in young women. Contraception, 2009, 79, 35-40.	1.5	47
9	Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome. Ultrasound in Obstetrics and Gynecology, 2012, 39, 341-347.	1.7	47
10	Effects of the levonorgestrel-releasing intrauterine system on cell proliferation, Fas expression and steroid receptors in endometriosis lesions and normal endometrium. Human Reproduction, 2009, 24, 2736-2745.	0.9	46
11	Effects of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers in patients with endometriosis: a comparative study with the GnRH analogue. Contraception, 2010, 81, 117-122.	1.5	41
12	Use of the etonogestrel-releasing implant is associated with hypoactivation of the coagulation cascade. Human Reproduction, 2007, 22, 2196-2201.	0.9	40
13	Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome. Molecular and Cellular Biochemistry, 2011, 353, 251-257.	3.1	37
14	Immediate postpartum initiation of etonogestrel-releasing implant: A randomized controlled trial on breastfeeding impact. Contraception, 2015, 92, 536-542.	1.5	36
15	The levonorgestrel-releasing intrauterine system and endometriosis staging. Fertility and Sterility, 2007, 87, 1231-1234.	1.0	33
16	Contracepção hormonal e sistema cardiovascular. Arquivos Brasileiros De Cardiologia, 2011, 96, e81-e89.	0.8	33
17	Hormonal contraception in women with polycystic ovary syndrome: choices, challenges, and noncontraceptive benefits. Open Access Journal of Contraception, 2017, Volume 8, 13-23.	1.4	32
18	PRENACEL – a mHealth messaging system to complement antenatal care: a cluster randomized trial. Reproductive Health, 2017, 14, 146.	3.1	32

#	ARTICLE	IF	CITATIONS
19	The Frequency of Metabolic Syndrome is Higher Among PCOS Brazilian Women With Menstrual Irregularity Plus Hyperandrogenism. <i>Reproductive Sciences</i> , 2011, 18, 1230-1236.	2.5	30
20	Metabolic and cardiovascular impact of oral contraceptives in polycystic ovary syndrome. <i>International Journal of Clinical Practice</i> , 2009, 63, 160-169.	1.7	29
21	Add-back therapy with GnRH analogues for uterine fibroids. <i>The Cochrane Library</i> , 2015, 2015, CD010854.	2.8	28
22	The effects of 2 mg chlormadinone acetate/30 mcg ethinylestradiol, alone or combined with spironolactone, on cardiovascular risk markers in women with polycystic ovary syndrome. <i>Contraception</i> , 2012, 86, 268-275.	1.5	24
23	Body Composition Characteristics Predict Sexual Functioning in Obese Women With or Without PCOS. <i>Journal of Sex and Marital Therapy</i> , 2015, 41, 227-237.	1.5	24
24	Cytomegalovirus Urinary Shedding in HIV-infected Pregnant Women and Congenital Cytomegalovirus Infection. <i>Clinical Infectious Diseases</i> , 2017, 65, 405-413.	5.8	21
25	Emergency Contraception for Adolescents and Young Adults: Guidance for Health Care Professionals. <i>Journal of Adolescent Health</i> , 2016, 58, 245-248.	2.5	20
26	Best Practices for Counseling Adolescents about the Etonogestrel Implant. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2020, 33, 448-454.	0.7	19
27	Ethinylestradiol and estradiol have different effects on oxidative stress and nitric oxide synthesis in human endothelial cell cultures. <i>Fertility and Sterility</i> , 2010, 94, 1578-1582.	1.0	18
28	Contemporary Hormonal Contraception and the Risk of Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1263-1266.	27.0	18
29	Effects of the etonogestrel-releasing contraceptive implant inserted immediately postpartum on maternal hemostasis: A randomized controlled trial. <i>Thrombosis Research</i> , 2012, 130, 355-360.	1.7	17
30	Combined Oral Contraceptive for Treatment of Women with Uterine Fibroids and Abnormal Uterine Bleeding: A Systematic Review. <i>Gynecologic and Obstetric Investigation</i> , 2015, 79, 145-152.	1.6	17
31	Neurologist knowledge about interactions between antiepileptic drugs and contraceptive methods. <i>International Journal of Gynecology and Obstetrics</i> , 2016, 134, 264-267.	2.3	17
32	Timing of Etonogestrel-Releasing Implants and Growth of Breastfed Infants. <i>Obstetrics and Gynecology</i> , 2017, 130, 100-107.	2.4	17
33	Controlled ovarian stimulation with exclusive FSH followed by stimulation with hCG alone, FSH alone or hMG. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2007, 130, 99-106.	1.1	16
34	Progesterone receptor, bc1-2 and bax expression in meningiomas. <i>Journal of Neuro-Oncology</i> , 2002, 56, 35-41.	2.9	15
35	Effects of combined oral contraceptives containing levonorgestrel or chlormadinone on the endothelium. <i>Contraception</i> , 2013, 87, 766-772.	1.5	15
36	Effect of intracervical anesthesia on pain associated with the insertion of the levonorgestrel-releasing intrauterine system in women without previous vaginal delivery: a RCT. <i>Human Reproduction</i> , 2014, 29, 2439-2445.	0.9	15

#	ARTICLE	IF	CITATIONS
37	Factors associated with nonadherence to instructions for using the Nestorone®/ethinyl estradiol contraceptive vaginal ring. <i>Contraception</i> , 2018, 97, 415-421.	1.5	15
38	Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?. <i>Contraception</i> , 2019, 100, 264-268.	1.5	15
39	Cardiovascular risk factors are reduced with a low dose of acarbose in obese patients with polycystic ovary syndrome. <i>Fertility and Sterility</i> , 2007, 88, 519-522.	1.0	14
40	Tibolone in postmenopausal women with systemic lupus erythematosus: A pilot study. <i>Maturitas</i> , 2009, 62, 311-316.	2.4	13
41	Safety of hormonal contraception for obese women. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1387-1393.	2.4	12
42	Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects. <i>Reproductive Sciences</i> , 2016, 23, 877-884.	2.5	10
43	Bleeding profile associated with 1-year use of the segesterone acetate/ethinyl estradiol contraceptive vaginal system: pooled analysis from Phase 3 trials. <i>Contraception</i> , 2019, 100, 438-444.	1.5	10
44	Transitory reduction of platelet aggregation with the use of etonogestrel implant in healthy women. <i>Thrombosis and Haemostasis</i> , 2005, 94, 682-683.	3.4	9
45	Small for gestational age babies are not related to changes in markers of adipose tissue dysfunction during reproductive age. <i>Early Human Development</i> , 2014, 90, 231-235.	1.8	9
46	Effects of two contraceptives containing drospirenone on blood pressure in normotensive women. <i>Blood Pressure Monitoring</i> , 2015, 20, 310-315.	0.8	9
47	Low-dose progestin-releasing contraceptives are associated with higher pain threshold in healthy women. <i>Fertility and Sterility</i> , 2015, 104, 1182-1189.	1.0	9
48	Nutritional Counseling Promotes Changes in the Dietary Habits of Overweight and Obese Adolescents with Polycystic Ovary Syndrome. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2017, 39, 692-696.	0.8	9
49	Cardiovascular risk markers among obese women using the levonorgestrel-releasing intrauterine system: A randomised controlled trial. <i>Obesity Research and Clinical Practice</i> , 2017, 11, 687-693.	1.8	9
50	Timing of postpartum etonogestrel-releasing implant insertion and bleeding patterns, weight change, 12-month continuation and satisfaction rates: a randomized controlled trial. <i>Contraception</i> , 2019, 100, 258-263.	1.5	9
51	Endocrine Disrupters: Potential Risk Factors Affecting Sexual Function in Both Men and Women. <i>Journal of Sexual Medicine</i> , 2012, 9, 941-942.	0.6	8
52	Oral anticoagulant therapy does not modify the bleeding pattern associated with the levonorgestrel-releasing intrauterine system in women with thrombophilia and/or a history of thrombosis. <i>Contraception</i> , 2014, 89, 48-53.	1.5	8
53	Intracervical block for levonorgestrel-releasing intrauterine system placement among nulligravid women: a randomized double-blind controlled trial. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 222, 245.e1-245.e10.	1.3	7
54	Hormônios femininos e hemostasia. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2007, 29, 538-547.	0.8	5

#	ARTICLE	IF	CITATIONS
55	The telomere attrition rate is not accelerated in women born small for gestational age: A birth cohort study. <i>Gene</i> , 2017, 600, 16-20.	2.2	5
56	Flow-mediated dilatation in polycystic ovary syndrome women. <i>Fertility and Sterility</i> , 2009, 91, e23.	1.0	4
57	Oral Contraceptive Containing Chlormadinone Acetate and Ethinylestradiol Reduces Plasma Concentrations of Matrix Metalloproteinase-2 in Women with Polycystic Ovary Syndrome. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2012, 111, 211-216.	2.5	4
58	Comparison of the hemostatic effects of a levonorgestrel-releasing intrauterine system and leuprolide acetate in women with endometriosis: A randomized clinical trial. <i>Thrombosis Research</i> , 2014, 134, 1193-1197.	1.7	4
59	Long-Acting Reversible Contraceptives: An Important Approach to Reduce Unintended Pregnancies. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2016, 38, 207-209.	0.8	4
60	Does the Access to Sun Exposure Ensure Adequate Levels of 25-Hydroxyvitamin D?. <i>Revista Brasileira De Ginecologia E Obstetricia</i> , 2017, 39, 102-109.	0.8	4
61	A pilot study of levonorgestrel concentrations and bleeding patterns in women with epilepsy using a levonorgestrel IUD and treated with antiepileptic drugs. <i>Contraception</i> , 2019, 99, 251-255.	1.5	4
62	Effect of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 148, 381-385.	2.3	4
63	Factors associated with missing strings and expulsion after postplacental insertion of copper T380A intrauterine devices. <i>International Journal of Gynecology and Obstetrics</i> , 2022, 157, 67-75.	2.3	4
64	Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy. <i>European Journal of Contraception and Reproductive Health Care</i> , 2016, 21, 285-289.	1.5	3
65	Practical training of health care providers in insertion of contraceptive implants: findings from two Brazilian centres. <i>European Journal of Contraception and Reproductive Health Care</i> , 2021, 26, 499-502.	1.5	3
66	Three-dimensional ultrasound imaging of an intrauterine device showing copper corrosion. <i>Ultrasound in Obstetrics and Gynecology</i> , 2013, 42, 606-607.	1.7	2
67	New Developments in Vaginal Rings for Contraception. <i>Current Obstetrics and Gynecology Reports</i> , 2014, 3, 143-149.	0.8	2
68	Sociodemographic factors and prenatal care behaviors associated with unplanned pregnancy in a Brazilian birth cohort study. <i>International Journal of Gynecology and Obstetrics</i> , 2020, 151, 237-243.	2.3	2
69	Sexual Function of Women Practicing Sex in Nonconventional Settings. <i>Journal of Sex and Marital Therapy</i> , 2015, 41, 294-303.	1.5	1
70	Predictors of severe pain during insertion of the levonorgestrel 52µg intrauterine system among nulligravid women. <i>Contraception</i> , 2020, 102, 267-269.	1.5	1
71	Drospirenone: a Latin American perspective for oestrogen-free oral contraception. <i>European Journal of Contraception and Reproductive Health Care</i> , 2021, 26, 73-78.	1.5	1
72	Pharmacodynamics and pharmacokinetics of a copper intrauterine contraceptive system releasing ulipristal acetate: A randomized proof-of-concept study. <i>Contraception</i> , 2021, 104, 327-336.	1.5	1

73	Avalia��o da fun��o das c��lulas beta pancre��ticas atrav��s do modelo matem��tico de HOMA em portadoras de s��ndrome dos ov��rios polic��sticos: compara��o entre obesas e n��o-obesas. Revista Brasileira De Ginecologia E Obstetricia, 2007, 29, 141-146.	0.8	1
74	LH as a low dose chorionic gonadotropin for late stage ovulation induction: comparison with human menopausal gonadotropin. International Congress Series, 2004, 1271, 89-92.	0.2	0
75	Title is missing!. Fertility and Sterility, 2007, 88, 765-766.	1.0	0
76	The levonorgestrel-releasing intrauterine system (LNG-IUS) and endometriosis: molecular effects on��the topic and on the ectopic endometrium. Fertility and Sterility, 2007, 88, S209-S210.	1.0	0
77	Absence of adverse hepatic or renal effects with the etonogestrel-releasing contraceptive implant inserted immediately postpartum. Open Access Journal of Contraception, 2010, , 127.	1.4	0